Regulus, Sanofi-Aventis form $750M partnership

Biotech drugmaker Regulus Therapeutics Inc. said Tuesday it will team up with Sanofi-Aventis SA, one of the world’s largest drug companies, in a drug development deal that could be worth more than $750 million.

Regulus and Sanofi-Aventis will work on as many as four drugs that use microRNA, or small RNA molecules that can treat diseases by turning parts of genes on or off. Their first focus will be fibrosis, a group of diseases that cause scarring inside organs.